{"id":68887,"date":"2026-03-02T09:46:41","date_gmt":"2026-03-02T09:46:41","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=68887"},"modified":"2026-10-15T10:34:00","modified_gmt":"2026-10-15T10:34:00","slug":"pt-141","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/pt-141\/","title":{"rendered":"PT-141"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Quick Answer \u2014 What is PT-141?<\/h3>\n<p style=\"margin: 0;\"><strong>PT-141 (bremelanotide)<\/strong> is a synthetic melanocortin receptor agonist acting at the <strong>MC4R<\/strong> in the central nervous system. Unlike PDE5 inhibitors that target vascular physiology, PT-141 activates CNS arousal pathways via dopamine release in the medial preoptic area. It is FDA-approved under the trade name Vyleesi for female hypoactive sexual desire disorder. Supplied in 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>What you get with MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/reviews\/\">customer reviews<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Every order is covered by our <a href=\"https:\/\/medsbase.com\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days, we reship it.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS Number<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">189691-06-3<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molecular Formula<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>50<\/sub>H<sub>68<\/sub>N<sub>14<\/sub>O<sub>10<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molecular Weight<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1025.18 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequence<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Form<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized powder (or as supplied)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Purity<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC verified, COA on request)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Storage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized: 2\u20138\u00a0\u00b0C (refrigerator) for working stock; \u221220\u00a0\u00b0C for long-term storage of unopened vials. Reconstituted: 2\u20138\u00a0\u00b0C, use within ~30 days. Protect from light. Do not freeze\u2013thaw the reconstituted solution.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubility<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bacteriostatic water (recommended) or sterile water for shorter use windows<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>What Is PT-141?<\/h2>\n<p><strong>PT-141<\/strong> (international nonproprietary name: <strong>bremelanotide<\/strong>) is a synthetic seven-amino-acid cyclic peptide analog of alpha-melanocyte stimulating hormone (\u03b1-MSH). It belongs to the <strong>melanocortin<\/strong> family and was originally developed from studies of Melanotan II, which users noted produced unexpected arousal effects as a side effect during tanning-related studies. Sequence (cyclic): Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Molecular weight approximately 1,025\u00a0Da. PT-141 binds melanocortin receptors with preference for the <strong>MC4 receptor (MC4R)<\/strong>, with measurable activity at MC1R, MC3R, and MC5R. The CNS-arousal signal is attributed primarily to MC4R activation in the hypothalamic medial preoptic area. Bremelanotide was FDA-approved in June 2019 under the trade name <strong>Vyleesi<\/strong> specifically for generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The specialist form sold by peptide-studies suppliers is chemically identical but is <strong>not<\/strong> the FDA-approved therapeutic product and is for clinical studies use only. For deeper mechanism and published studies context, see our full <a href=\"https:\/\/medsbase.com\/pt-141-bremelanotide-peptide-guide\/\">PT-141 guide<\/a>. <\/p>\n<h2>Mechanism of Action \u2014 Central (Not Vascular) Arousal Pathway<\/h2>\n<p>PT-141&#8217;s most important mechanistic distinction is that it acts <strong>centrally<\/strong> \u2014 in the brain \u2014 rather than peripherally on vascular smooth muscle. This makes it fundamentally different from PDE5 inhibitors (Viagra, Cialis) which target the vascular nitric-oxide pathway to produce erection via blood-flow changes:<\/p>\n<ul>\n<li><strong>MC4 receptor agonism<\/strong> \u2014 PT-141 binds the MC4R in the hypothalamic medial preoptic area (mPOA) and paraventricular nucleus. MC4R activation in these regions is a recognised upstream regulator of sexual arousal pathways in both males and females.<\/li>\n<li><strong>Dopaminergic signaling<\/strong> \u2014 MC4R activation in the mPOA triggers dopamine release in regions associated with appetitive behavior and arousal. This downstream dopamine signal is thought to mediate the observed behavioral reported effects.<\/li>\n<li><strong>Independence from vascular physiology<\/strong> \u2014 because PT-141 acts in the brain rather than on vasculature, its effects are independent of nitric-oxide availability or endothelial function. This is the mechanistic basis for PT-141 studies in populations where PDE5 inhibitors are ineffective (central-origin sexual dysfunction, post-SSRI dysfunction, spinal-cord studies).<\/li>\n<\/ul>\n<p>Because melanocortin receptors are expressed in multiple tissues, PT-141 has studies utility beyond sexual-function studies \u2014 including hemorrhagic shock studies (MC4R vasopressor effects), appetitive-behavior neuroscience, and comparative melanocortin pharmacology. <\/p>\n<h2>Published Evidence<\/h2>\n<p>PT-141 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Central-arousal pathway studies<\/strong> \u2014 rodent and in-vitro models of CNS sexual-function signaling (King et al., Pharmacol Biochem Behav 2010)<\/li>\n<li><strong>Melanocortin receptor pharmacology<\/strong> \u2014 MC4R signaling and downstream cAMP\/PKA pathway studies<\/li>\n<li><strong>Hemorrhagic shock studies<\/strong> \u2014 vasopressor-adjacent studies in trauma-model preclinical studies<\/li>\n<li><strong>Comparative arousal pharmacology<\/strong> \u2014 benchmarking vs PDE5 inhibitors (vascular) and other non-vascular arousal compounds<\/li>\n<li><strong>Neuroscience studies<\/strong> \u2014 dopamine mPOA signaling and appetitive-behavior studies in rodent behavioral models<\/li>\n<li><strong>Receptor selectivity profiling<\/strong> \u2014 MC3R vs MC4R selectivity studies in melanocortin analog studies<\/li>\n<\/ul>\n<p>For broader context on peptides in the sexual-health studies space see <a href=\"https:\/\/medsbase.com\/peptides\/\">the peptides catalog<\/a>. <\/p>\n<h2>Available Strengths<\/h2>\n<p>MedsBase stocks PT-141 in a single 10\u00a0mg lyophilized vial strength, available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Vial Strength<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typical Use Case<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Pack Sizes<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 supports approximately 6 administrations per vial at the 1.5\u00a0mg titration dose<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20, or 30 vials<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The 10\u00a0mg vial format matches typical protocol usage \u2014 1\u20132\u00a0mg per administration on an as-needed basis, with 1.5\u00a0mg being a common titration starting point in published protocols. Supplied as lyophilized powder at 99%+ HPLC purity. <\/p>\n<h2>How It Compares \u2014 PT-141 vs PDE5 Inhibitors<\/h2>\n<p>PT-141 and PDE5 inhibitors target sexual function via entirely different mechanisms. Understanding the difference is central to any comparative studies using PT-141:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterion<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">PT-141 (Bremelanotide)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">PDE5 Inhibitors (sildenafil, tadalafil, etc.)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mechanism<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Central (CNS) melanocortin MC4R agonism<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Peripheral (vascular) PDE5 inhibition<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Target tissue<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Hypothalamus (mPOA)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Vascular smooth muscle<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Requires NO signaling?<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No \u2014 independent of vascular pathway<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Yes \u2014 amplifies endogenous NO<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Route<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Subcutaneous injection<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Oral tablet<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>FDA-approved indication<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Female HSDD (Vyleesi, 2019)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Male ED, PAH<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Studies populations<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Central-origin arousal studies, post-SSRI<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Peripheral vascular \/ endothelial studies<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Storage and Reconstitution<\/h2>\n<p><strong>Before reconstitution:<\/strong> store lyophilized vials refrigerated at 2\u20138\u00a0\u00b0C in original packaging, stable up to 36 months. Avoid freeze-thaw cycles on the powder. <strong>Reconstitution procedure:<\/strong> inject bacteriostatic water down the side wall of the peptide vial per the chart above. Swirl gently \u2014 do <strong>not<\/strong> shake \u2014 and allow 5\u201310 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless. <strong>After reconstitution:<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days. Do not freeze reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity. <\/p>\n<h2 id=\"faqs\">Frequently Asked Questions<\/h2>\n<h3>What is PT-141 used for in studies?<\/h3>\n<p>PT-141 is used in studies investigating central-arousal pathway signaling, melanocortin receptor pharmacology (especially MC4R), hemorrhagic shock vasopressor effects, neuroscience of appetitive behavior, and comparative arousal pharmacology versus PDE5 inhibitors. It is sold here strictly for clinical studies use only. <\/p>\n<h3>How is PT-141 different from Viagra or Cialis?<\/h3>\n<p>PT-141 acts centrally, in the brain \u2014 it binds melanocortin MC4 receptors in the hypothalamus to trigger arousal via dopamine signaling. PDE5 inhibitors (sildenafil \/ Viagra, tadalafil \/ Cialis) act peripherally on vascular smooth muscle to enhance blood flow via nitric oxide amplification. The mechanisms are entirely separate, which is why PT-141 studies includes populations where PDE5 inhibitors are ineffective. <\/p>\n<h3>What is the typical PT-141 dose?<\/h3>\n<p>Published preclinical protocols and the FDA-approved Vyleesi label describe 1.75\u00a0mg per administration as needed, with some protocols using 1\u20132\u00a0mg titration. A 10\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 5\u00a0mg\/mL \u2014 30 ticks on a U-100 syringe delivers 1.5\u00a0mg. <\/p>\n<h3>Is PT-141 FDA approved?<\/h3>\n<p>Bremelanotide (PT-141) is FDA-approved under the trade name <strong>Vyleesi<\/strong> (AMAG Pharmaceuticals, 2019) specifically for generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The specialist form sold by peptide suppliers is chemically identical but is <strong>not<\/strong> the approved therapeutic product and should not be used for therapy. <\/p>\n<h3>How should PT-141 be stored?<\/h3>\n<p>Lyophilized vials: refrigerated at 2\u20138\u00a0\u00b0C in original packaging, stable up to 36 months. Reconstituted solution: refrigerated at 2\u20138\u00a0\u00b0C, use within 30 days. Do not freeze reconstituted solution \u2014 freeze-thaw cycles degrade the peptide. <\/p>\n<h3>How do I reconstitute PT-141?<\/h3>\n<p>Follow the reconstitution chart above. Add bacteriostatic water down the side wall of the vial, swirl gently, and allow 5\u201310 minutes for full dissolution. Do <strong>not<\/strong> shake the vial. The chart provides three dilution options depending on the per-administration dose size your protocol requires. <\/p>\n<h3>What strengths does MedsBase stock?<\/h3>\n<p>MedsBase carries PT-141 in 10\u00a0mg lyophilized vials, available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis on request. <\/p>\n<h3>Is PT-141 the same as Melanotan II?<\/h3>\n<p>No, but they share an ancestor. Both are melanocortin analogs, and PT-141 was developed from observations during Melanotan II studies. Melanotan II is a broader melanocortin agonist (MC1R\/MC3R\/MC4R\/MC5R) with significant melanocyte-stimulating activity (tanning effect). PT-141 was refined to reduce MC1R activity (minimal tanning) while preserving MC4R-mediated arousal signal. <\/p>\n<h3>Does PT-141 cause side reported effects?<\/h3>\n<p>Published studies and the Vyleesi clinical trial data report the most common effects as transient nausea, flushing, and mild headache after administration. Transient blood-pressure elevation has been noted; Vyleesi carries a precaution for patients with uncontrolled hypertension or cardiovascular disease. A small proportion of studies subjects experience transient focal hyperpigmentation (related to residual MC1R activity). <\/p>\n<h3>When is PT-141 typically used versus PDE5 inhibitors in studies?<\/h3>\n<p>PT-141 protocols are typically selected when the studies question involves central-origin sexual dysfunction (not vascular), post-SSRI sexual dysfunction, female sexual-desire studies, or comparative central-vs-peripheral pharmacology. PDE5 inhibitors remain the reference for vascular-ED studies. <\/p>\n<h3>Can I take PT-141 with other peptides in studies?<\/h3>\n<p>PT-141 acts through a distinct receptor family (melanocortin) from the GHRP\/GHRH peptides (<a href=\"https:\/\/medsbase.com\/ipamorelin\/\">ipamorelin<\/a>, <a href=\"https:\/\/medsbase.com\/cjc-1295-with-dac\/\">CJC-1295<\/a>), healing peptides (<a href=\"https:\/\/medsbase.com\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/tb-500\/\">TB-500<\/a>), and metabolic peptides (<a href=\"https:\/\/medsbase.com\/retatrutide\/\">retatrutide<\/a>). Pharmacological interactions are minimal, though protocols should account for independent side-effect profiles. <\/p>\n<h3>What is the half-life of PT-141?<\/h3>\n<p>PT-141 (bremelanotide) has a plasma half-life of approximately 2.7 hours, based on pharmacokinetic data from clinical studies of the approved Vyleesi formulation. Reconstituted solutions should be stored at 4 \u00b0C and used within 30 days. <\/p>\n<h3>How does PT-141 differ from Melanotan II?<\/h3>\n<p>PT-141 is a metabolite of Melanotan II with reduced MC1R activity and relatively more selective MC4R activity \u2014 giving it a clinical development path focused on central arousal studies that resulted in FDA approval (Vyleesi). Melanotan II has broader melanocortin receptor activity (MC1R\u2013MC5R) and is studied for UV-induced pigmentation as well as arousal. In contexts, PT-141 has the more characterised clinical dataset of the two. <\/p>\n<h3>Can I order PT-141 for international shipping?<\/h3>\n<p>Yes. MedsBase ships PT-141 worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. Orders ship in temperature-controlled packaging with full tracking. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Recovery and Performance<\/h2>\n<ul>\n<li><a href=\"\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Body Protection Compound \u2014 tendon, ligament, gut recovery<\/li>\n<li><a href=\"\/tb-500\/\"><strong>TB-500<\/strong><\/a> \u2014 Thymosin Beta-4 fragment \u2014 soft tissue and vascular recovery<\/li>\n<li><a href=\"\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Selective ghrelin agonist \u2014 clean GH pulse without cortisol\/prolactin<\/li>\n<li><a href=\"\/cjc-1295-with-dac\/\"><strong>CJC-1295 with DAC<\/strong><\/a> \u2014 GHRH analog with extended half-life<\/li>\n<li><a href=\"\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Copper peptide \u2014 skin and connective tissue regeneration<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Further Reading<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Learn the science behind this peptide<\/strong><\/p>\n<p style=\"margin: 0;\">Read our complete evidence-based guide: <a href=\"https:\/\/medsbase.com\/pt-141-bremelanotide-peptide-guide\/\"><strong>PT-141 (Bremelanotide) \u2014 mechanism, Vyleesi history, protocols<\/strong><\/a>. Covers melanocortin receptor pharmacology, CNS arousal pathway biology, FDA approval history, published studies dosing ranges, reconstitution protocols, and safety notes.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u2705 \u6027\u7684\u6b32\u6c42\u3068\u8208\u596e\u3092\u9ad8\u3081\u307e\u3059<br \/>\n\u2705 \u4e2d\u67a2\u795e\u7d4c\u7cfb\u306e\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u3092\u30b5\u30dd\u30fc\u30c8<br \/>\n\u2705 \u6027\u7684\u610f\u6b32\u3068\u53cd\u5fdc\u6027\u3092\u4fc3\u9032<br \/>\n\u2705 \u6c17\u5206\u95a2\u9023\u306e\u795e\u7d4c\u4f1d\u9054\u7269\u8cea\u6d3b\u6027\u3092\u5411\u4e0a<br \/>\n\u2705 \u5168\u4f53\u7684\u306a\u6027\u7684\u5065\u5eb7\u3092\u6539\u5584<\/p>\n<p><strong>PT\u2011141<\/strong> \u5408\u6210\u30da\u30d7\u30c1\u30c9\u5316\u5408\u7269\u3092\u542b\u307f\u307e\u3059\u3002<\/p>","protected":false},"featured_media":70974,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5456,5455],"class_list":["post-68887","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-bremelanotide","product_tag-pt-141-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/68887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=68887"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/70974"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=68887"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=68887"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=68887"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=68887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}